IL132918A - Pharmacological formulations containing vericonazole and a derivative of cyclodextrin - Google Patents

Pharmacological formulations containing vericonazole and a derivative of cyclodextrin

Info

Publication number: IL132918A
Authority: IL; Israel
Prior art keywords: formulation; voriconazole; cyclodextrin; cyclodextrin derivative; derivative
Prior art date: 1997-06-21

Application number

IL13291898A

Other languages

English (en)

Hebrew (he)

Other versions

IL132918A0 (en

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-21

Filing date

1998-06-02

Publication date

2001-09-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL132918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-02 Application filed by Pfizer filed Critical Pfizer

2001-03-19 Publication of IL132918A0 publication Critical patent/IL132918A0/xx

2001-09-13 Publication of IL132918A publication Critical patent/IL132918A/en

Links

BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 title claims abstract description 19
229960004740 voriconazole Drugs 0.000 title claims abstract description 18
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims abstract description 15
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 5
238000009472 formulation Methods 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
-1 alkali metal salt Chemical class 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 2
230000000843 anti-fungal effect Effects 0.000 abstract 1
229920000858 Cyclodextrin Polymers 0.000 description 8
NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 6
239000001116 FEMA 4028 Substances 0.000 description 5
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 5
235000011175 beta-cyclodextrine Nutrition 0.000 description 5
229960004853 betadex Drugs 0.000 description 5
238000004108 freeze drying Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000008215 water for injection Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000000034 method Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Nanotechnology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL13291898A 1997-06-21 1998-06-02 Pharmacological formulations containing vericonazole and a derivative of cyclodextrin IL132918A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9713149.4A GB9713149D0 (en)	1997-06-21	1997-06-21	Pharmaceutical formulations
PCT/EP1998/003477 WO1998058677A1 (en)	1997-06-21	1998-06-02	Pharmaceutical formulations containing voriconazole

Publications (2)

Publication Number	Publication Date
IL132918A0 IL132918A0 (en)	2001-03-19
IL132918A true IL132918A (en)	2001-09-13

Family

ID=10814734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13291898A IL132918A (en)	1997-06-21	1998-06-02	Pharmacological formulations containing vericonazole and a derivative of cyclodextrin

Country Status (47)

Country	Link
US (1)	US6632803B1 (sr)
EP (1)	EP1001813B8 (sr)
JP (2)	JP2000513029A (sr)
KR (1)	KR100372988B1 (sr)
CN (1)	CN1125653C (sr)
AP (1)	AP912A (sr)
AR (1)	AR015900A1 (sr)
AT (1)	ATE238812T1 (sr)
AU (1)	AU724799B2 (sr)
BG (1)	BG64584B1 (sr)
BR (1)	BRPI9809468B8 (sr)
CA (1)	CA2295035C (sr)
CO (1)	CO4940450A1 (sr)
CZ (1)	CZ289570B6 (sr)
DE (1)	DE69814091T2 (sr)
DK (1)	DK1001813T3 (sr)
DZ (1)	DZ2523A1 (sr)
EA (1)	EA001924B1 (sr)
EG (1)	EG23910A (sr)
ES (1)	ES2195355T3 (sr)
GB (1)	GB9713149D0 (sr)
HR (1)	HRP980341B1 (sr)
HU (1)	HU228338B1 (sr)
ID (1)	ID22939A (sr)
IL (1)	IL132918A (sr)
IS (1)	IS2004B (sr)
MA (1)	MA26508A1 (sr)
ME (1)	ME00907B (sr)
MY (1)	MY118151A (sr)
NO (1)	NO313125B1 (sr)
NZ (1)	NZ501066A (sr)
OA (1)	OA11232A (sr)
PA (1)	PA8453201A1 (sr)
PE (1)	PE84899A1 (sr)
PL (1)	PL191295B1 (sr)
PT (1)	PT1001813E (sr)
RS (1)	RS49633B (sr)
SA (1)	SA98190159B1 (sr)
SI (1)	SI1001813T1 (sr)
SK (1)	SK282946B6 (sr)
TN (1)	TNSN98090A1 (sr)
TR (1)	TR199903191T2 (sr)
TW (1)	TW406023B (sr)
UA (1)	UA57083C2 (sr)
UY (1)	UY25055A1 (sr)
WO (1)	WO1998058677A1 (sr)
ZA (1)	ZA985364B (sr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9818258D0 (en) *	1998-08-21	1998-10-14	Pfizer Ltd	Antifungal compositions
PE20020300A1 (es)	2000-08-22	2002-05-10	Pharmacia Corp	Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es)	2000-10-10	2003-09-10	Upjohn Co	Composiciones de antibiotico topico para el tratamiento de infecciones oculares
DE60327225D1 (de) *	2002-08-20	2009-05-28	Bristol Myers Squibb Co	Aripiprazol-komplex-formulierung und verfahren
GB0327390D0 (en) *	2003-11-25	2003-12-31	Pfizer Ltd	Pharmaceutical formulations
CN1889943A (zh) *	2003-12-08	2007-01-03	美国亚利桑那大学董事会	协同抗癌组合物
WO2006004795A2 (en)	2004-06-25	2006-01-12	The Johns Hopkins University	Angiogenesis inhibitors
US20100204178A1 (en)	2006-10-02	2010-08-12	James Cloyd	Novel parenteral carbamazepine formulation
US20070082870A1 (en) *	2005-10-11	2007-04-12	Buchanan Charles M	Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es)	2006-07-13	2008-10-01	Medichem Sa	Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) *	2006-09-14	2013-01-02	大道隆达（北京）医药科技发展有限公司	伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) *	2007-06-19	2008-09-30	Рудолф ПОДЛИПСКИ	Отоплителен съд за експресно локално загряване навода
EP2018866A1 (en) *	2007-07-27	2009-01-28	Sandoz AG	Pharmaceutical compositions containing voriconazole
US8192721B2 (en) *	2007-12-13	2012-06-05	Verrow Pharmaceuticals, Inc.	Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US20110224232A1 (en) *	2008-05-06	2011-09-15	Board Of Regents, The University Of Texas System	Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
US20110105448A1 (en) *	2008-06-06	2011-05-05	Glenmark Pharmaceuticals Limited	Stable Topical Formulation Comprising Voriconazole
CN101390825B (zh) *	2008-10-01	2010-12-29	山东省眼科研究所	一种伏立康唑眼内释药系统
BRPI0919668A2 (pt)	2008-10-21	2018-05-29	Onyx Therapeutics, Inc.	terapia de combinação com epóxi-cetonas de peptídeo
CN101444510B (zh) *	2008-12-31	2011-03-09	南京卡文迪许生物工程技术有限公司	含有伏立康唑的药物制剂及其制备方法
WO2011020605A1 (en)	2009-08-19	2011-02-24	Ratiopharm Gmbh	Process for the production of coevaporates and complexes comprising voriconazole and cyclodextrin
WO2011064558A2 (en)	2009-11-30	2011-06-03	Cipla Limited	Pharmaceutical composition
JP6008849B2 (ja)	2010-06-29	2016-10-19	メルク・シャープ・エンド・ドーム・コーポレイション	置換β−シクロデキストリンにより安定化されたポサコナゾール静脈注射用溶液製剤
EP2409699B1 (en)	2010-07-23	2014-04-30	Combino Pharm, S.L.	Stable compositions of voriconazole
CN102058519B (zh) *	2010-11-19	2013-01-02	苏州特瑞药业有限公司	一种伏立康唑缓释栓剂及其制备方法
PL2720723T3 (pl)	2011-06-15	2018-10-31	Synthon Bv	Stabilizowana kompozycja worykonazolu
EP2561863A1 (en)	2011-08-22	2013-02-27	Farmaprojects, S.A.U.	Pharmaceutical compositions comprising voriconazole
US20150030668A1 (en) *	2012-01-05	2015-01-29	Frederick Timothy Guilford	Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions
US8853248B2 (en)	2012-04-05	2014-10-07	Hubert Maehr	(1,2,3-triazolyl)sulfonyl derivatives
CN104411334A (zh)	2012-05-08	2015-03-11	欧尼斯治疗公司	用于配制肽蛋白酶体抑制剂的环糊精络合法
US20150133472A1 (en)	2012-05-11	2015-05-14	Cipla Limited	Pharmaceutical composition
BR112015016331B1 (pt)	2013-01-11	2020-05-12	Xellia Pharmaceuticals Aps	Formulação farmacêutica estabilizada e método de estabilização de uma composição compreendendo voriconazol
EP2968595A2 (en)	2013-03-14	2016-01-20	Fresenius Kabi USA LLC	Voriconazole formulations
GB201312737D0 (en)	2013-07-17	2013-08-28	Univ Greenwich	Cyclodextrin
CN103690968A (zh) *	2013-11-21	2014-04-02	石药集团中奇制药技术（石家庄）有限公司	一种伏立康唑组合物及其制备方法
PT109117B (pt) *	2016-01-28	2019-02-01	Hovione Farm Sa	Complexação de ingredientes ativos farmacêuticos
WO2018091668A1 (en)	2016-11-18	2018-05-24	Aicuris Anti-Infective Cures Gmbh	Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
EP3584245A4 (en) *	2017-02-17	2020-08-26	Wuhan LL Science And Technology Development Co., Ltd.	TRIAZOLE ANTIBACTERIAL DERIVATIVE, ASSOCIATED PHARMACEUTICAL COMPOSITION AND USE
CN113750034A (zh) *	2020-06-05	2021-12-07	中南大学湘雅三医院	耳用温敏凝胶及其制备方法
CN116570558B (zh) *	2023-06-21	2023-12-26	广州仁恒医药科技股份有限公司	一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3346123A1 (de)	1983-12-21	1985-06-27	Janssen Pharmaceutica, N.V., Beerse	Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de)	1983-12-29	1985-07-11	Hoechst Ag, 6230 Frankfurt	Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en)	1988-08-13	1988-09-14	Pfizer Ltd	Triazole antifungal agents
KR0166088B1 (ko) *	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) *	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9002375D0 (en) *	1990-02-02	1990-04-04	Pfizer Ltd	Triazole antifungal agents
US5278175A (en) *	1990-02-02	1994-01-11	Pfizer Inc.	Triazole antifungal agents
GB9512961D0 (en)	1995-06-26	1995-08-30	Pfizer Ltd	Antifungal agents
GB9602080D0 (en)	1996-02-02	1996-04-03	Pfizer Ltd	Pharmaceutical compounds

1997
- 1997-06-21 GB GBGB9713149.4A patent/GB9713149D0/en active Pending
1998
- 1998-02-06 UA UA99126910A patent/UA57083C2/uk unknown
- 1998-05-05 TW TW087106918A patent/TW406023B/zh not_active IP Right Cessation
- 1998-06-02 CN CN98806446A patent/CN1125653C/zh not_active Expired - Lifetime
- 1998-06-02 NZ NZ501066A patent/NZ501066A/xx not_active IP Right Cessation
- 1998-06-02 DK DK98930793T patent/DK1001813T3/da active
- 1998-06-02 AU AU81104/98A patent/AU724799B2/en not_active Expired
- 1998-06-02 ES ES98930793T patent/ES2195355T3/es not_active Expired - Lifetime
- 1998-06-02 PL PL337692A patent/PL191295B1/pl unknown
- 1998-06-02 CA CA002295035A patent/CA2295035C/en not_active Expired - Lifetime
- 1998-06-02 TR TR1999/03191T patent/TR199903191T2/xx unknown
- 1998-06-02 HU HU0003323A patent/HU228338B1/hu unknown
- 1998-06-02 ME MEP-1999-681A patent/ME00907B/me unknown
- 1998-06-02 BR BRPI9809468A patent/BRPI9809468B8/pt not_active IP Right Cessation
- 1998-06-02 RS YUP-681/99A patent/RS49633B/sr unknown
- 1998-06-02 ID IDW991429A patent/ID22939A/id unknown
- 1998-06-02 DE DE69814091T patent/DE69814091T2/de not_active Expired - Lifetime
- 1998-06-02 CZ CZ19994096A patent/CZ289570B6/cs not_active IP Right Cessation
- 1998-06-02 KR KR10-1999-7012034A patent/KR100372988B1/ko not_active Expired - Lifetime
- 1998-06-02 SI SI9830469T patent/SI1001813T1/xx unknown
- 1998-06-02 IL IL13291898A patent/IL132918A/en not_active IP Right Cessation
- 1998-06-02 JP JP11503686A patent/JP2000513029A/ja not_active Withdrawn
- 1998-06-02 EA EA199900937A patent/EA001924B1/ru not_active IP Right Cessation
- 1998-06-02 WO PCT/EP1998/003477 patent/WO1998058677A1/en not_active Ceased
- 1998-06-02 US US09/402,289 patent/US6632803B1/en not_active Expired - Lifetime
- 1998-06-02 PT PT98930793T patent/PT1001813E/pt unknown
- 1998-06-02 AT AT98930793T patent/ATE238812T1/de active
- 1998-06-02 SK SK1593-99A patent/SK282946B6/sk not_active IP Right Cessation
- 1998-06-02 EP EP98930793.9A patent/EP1001813B8/en not_active Expired - Lifetime
- 1998-06-10 PA PA19988453201A patent/PA8453201A1/es unknown
- 1998-06-15 SA SA98190159A patent/SA98190159B1/ar unknown
- 1998-06-17 MA MA25117A patent/MA26508A1/fr unknown
- 1998-06-17 TN TNTNSN98090A patent/TNSN98090A1/fr unknown
- 1998-06-17 DZ DZ980133A patent/DZ2523A1/xx active
- 1998-06-18 AP APAP/P/1998/001268A patent/AP912A/en active
- 1998-06-18 AR ARP980102924A patent/AR015900A1/es active IP Right Grant
- 1998-06-19 PE PE1998000539A patent/PE84899A1/es not_active IP Right Cessation
- 1998-06-19 UY UY25055A patent/UY25055A1/es not_active IP Right Cessation
- 1998-06-19 ZA ZA9805364A patent/ZA985364B/xx unknown
- 1998-06-19 HR HR980341A patent/HRP980341B1/xx not_active IP Right Cessation
- 1998-06-20 MY MYPI98002792A patent/MY118151A/en unknown
- 1998-06-20 EG EG70998A patent/EG23910A/xx active
- 1998-06-23 CO CO98035641A patent/CO4940450A1/es unknown
1999
- 1999-11-12 NO NO19995565A patent/NO313125B1/no not_active IP Right Cessation
- 1999-11-15 BG BG103882A patent/BG64584B1/bg unknown
- 1999-11-15 IS IS5248A patent/IS2004B/is unknown
- 1999-12-10 OA OA9900277A patent/OA11232A/en unknown
2002
- 2002-03-27 JP JP2002088076A patent/JP5089004B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2002332234A (ja)	2002-11-22
CZ289570B6 (cs)	2002-02-13
CN1261287A (zh)	2000-07-26
DE69814091D1 (de)	2003-06-05
GB9713149D0 (en)	1997-08-27
ID22939A (id)	1999-12-16
DK1001813T3 (da)	2003-07-28
KR20010014006A (ko)	2001-02-26
TW406023B (en)	2000-09-21
DE69814091T2 (de)	2004-01-22
IL132918A0 (en)	2001-03-19
AU724799B2 (en)	2000-09-28
RS49633B (sr)	2007-08-03
EG23910A (en)	2007-12-30
HUP0003323A2 (hu)	2001-06-28
HRP980341A2 (en)	1999-02-28
ATE238812T1 (de)	2003-05-15
CA2295035A1 (en)	1998-12-30
SK282946B6 (sk)	2003-01-09
BG64584B1 (bg)	2005-08-31
ES2195355T3 (es)	2003-12-01
PT1001813E (pt)	2003-07-31
IS5248A (is)	1999-11-15
EP1001813B1 (en)	2003-05-02
EP1001813B8 (en)	2014-02-12
UY25055A1 (es)	2000-12-29
HUP0003323A3 (en)	2002-01-28
CN1125653C (zh)	2003-10-29
WO1998058677A1 (en)	1998-12-30
BR9809468B1 (pt)	2013-11-12
KR100372988B1 (ko)	2003-02-25
SI1001813T1 (en)	2004-02-29
TR199903191T2 (xx)	2000-09-21
AP912A (en)	2001-12-08
NO995565L (no)	1999-11-30
TNSN98090A1 (fr)	2005-03-15
ME00907B (me)	2007-08-03
PE84899A1 (es)	1999-09-17
NO313125B1 (no)	2002-08-19
EA001924B1 (ru)	2001-10-22
PA8453201A1 (es)	2000-05-24
AU8110498A (en)	1999-01-04
HRP980341B1 (en)	2001-12-31
YU68199A (sh)	2002-06-19
BR9809468A (pt)	2000-06-20
US6632803B1 (en)	2003-10-14
PL337692A1 (en)	2000-08-28
MY118151A (en)	2004-09-30
CO4940450A1 (es)	2000-07-24
NZ501066A (en)	2001-01-26
BG103882A (en)	2000-07-31
IS2004B (is)	2005-04-15
OA11232A (en)	2003-05-26
DZ2523A1 (fr)	2003-02-01
NO995565D0 (no)	1999-11-12
EA199900937A1 (ru)	2000-08-28
HK1027966A1 (en)	2001-02-02
JP2000513029A (ja)	2000-10-03
EP1001813A1 (en)	2000-05-24
HU228338B1 (en)	2013-03-28
BRPI9809468B8 (pt)	2022-01-18
SA98190159B1 (ar)	2005-12-21
CZ409699A3 (cs)	2000-02-16
AR015900A1 (es)	2001-05-30
AP9801268A0 (en)	1998-06-30
UA57083C2 (uk)	2003-06-16
CA2295035C (en)	2005-04-19
PL191295B1 (pl)	2006-04-28
SK159399A3 (en)	2000-06-12
JP5089004B2 (ja)	2012-12-05
ZA985364B (en)	1999-12-20
MA26508A1 (fr)	2004-12-20

Legal Events

Date	Code	Title	Description
2002-02-10	KB20	Patent renewed for 20 years
2018-12-31	EXP	Patent expired

Publication	Publication Date	Title
AP912A (en)	2001-12-08	Pharmaceutical-formulations containing voriconazole.
AU2003234285B2 (en)	2007-01-04	Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
KR100451485B1 (ko)	2004-10-06	푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
EP0216362A2 (en)	1987-04-01	Stable freeze-dried preparation of an anticancer platinum complex
MXPA04012426A (es)	2005-04-19	Preparacion liquida que contiene oligopeptidos.
US11730815B2 (en)	2023-08-22	Stable liquid pharmaceutical compositions comprising bendamustine
KR20160115827A (ko)	2016-10-06	인돌 화합물을 포함하는 제제 및 이의 제조 방법
MXPA99012075A (en)	2001-12-04	Pharmaceutical formulations containing voriconazole
WO2001047542A1 (en)	2001-07-05	Vancomycin preparations
CA2486571C (en)	2010-04-27	Pharmaceutical composition
NL8803126A (nl)	1989-07-17	Waterige preparaten die een piperidinylcyclopentylhepteenzuurderivaat bevatten.
HK1027966B (en)	2004-02-27	Pharmaceutical formulations containing voriconazole
HK1081451B (en)	2007-05-25	Medicinal composition